KR101217427B1 - Ｐｄｋ-1/ａｋｔ 신호전달 억제제 - Google Patents

Ｐｄｋ-1/ａｋｔ 신호전달 억제제 Download PDF

Info

Publication number
KR101217427B1
KR101217427B1 KR1020067008622A KR20067008622A KR101217427B1 KR 101217427 B1 KR101217427 B1 KR 101217427B1 KR 1020067008622 A KR1020067008622 A KR 1020067008622A KR 20067008622 A KR20067008622 A KR 20067008622A KR 101217427 B1 KR101217427 B1 KR 101217427B1
Authority
KR
South Korea
Prior art keywords
compound
phenyl
formula
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067008622A
Other languages
English (en)
Korean (ko)
Other versions
KR20060108651A (ko
Inventor
칭-지 첸
Original Assignee
더 오하이오 스테이트 유니버시티 리서치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34576689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101217427(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더 오하이오 스테이트 유니버시티 리서치 파운데이션 filed Critical 더 오하이오 스테이트 유니버시티 리서치 파운데이션
Publication of KR20060108651A publication Critical patent/KR20060108651A/ko
Application granted granted Critical
Publication of KR101217427B1 publication Critical patent/KR101217427B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020067008622A 2003-10-03 2006-05-03 Ｐｄｋ-1/ａｋｔ 신호전달 억제제 Expired - Lifetime KR101217427B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50861903P 2003-10-03 2003-10-03
US60/508,619 2003-10-03
US50981403P 2003-10-08 2003-10-08
US60/509,814 2003-10-08
PCT/US2004/032723 WO2005044130A1 (en) 2003-10-03 2004-10-04 Pdk-1/akt signaling inhibitors

Publications (2)

Publication Number Publication Date
KR20060108651A KR20060108651A (ko) 2006-10-18
KR101217427B1 true KR101217427B1 (ko) 2013-01-02

Family

ID=34576689

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067008622A Expired - Lifetime KR101217427B1 (ko) 2003-10-03 2006-05-03 Ｐｄｋ-1/ａｋｔ 신호전달 억제제

Country Status (9)

Country Link
EP (1) EP1696907B1 (enExample)
JP (1) JP4745971B2 (enExample)
KR (1) KR101217427B1 (enExample)
CN (1) CN1889949B (enExample)
CA (1) CA2566846C (enExample)
DK (1) DK1696907T3 (enExample)
ES (1) ES2420405T3 (enExample)
SI (1) SI1696907T1 (enExample)
WO (1) WO2005044130A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079566A1 (en) 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
CA2613522A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
JP2009519336A (ja) 2005-12-13 2009-05-14 ワイス ジベンゾナフチリジン誘導体およびそれらの使用方法
JP5399262B2 (ja) * 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
US20120108823A1 (en) * 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
RU2432112C1 (ru) * 2010-05-27 2011-10-27 Федеральное государственное учреждение "Саратовский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "СарНИИТО" Минздравсоцразвития России) Способ прогнозирования послеоперационных осложнений у больных с дегенеративно-дистрофическими поражениями суставов нижних конечностей
DE102010049877A1 (de) * 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
CA2818871A1 (en) * 2010-11-24 2012-05-31 The Ohio State University Research Foundation Integrin-linked kinase inhibitors
US10028933B2 (en) * 2015-07-22 2018-07-24 Ohio State Innovation Foundation Compositions and methods for inhibiting the growth of multi-drug resistant microbes
CN116462606B (zh) * 2022-01-12 2025-11-28 南京宁丹新药技术股份有限公司 一类酰胺衍生化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5954996A (en) 1994-07-13 1999-09-21 Centrix, Inc. Dental etch and package therefor
US20030203338A1 (en) 2002-04-24 2003-10-30 Levine Jonathan B. Tooth whitener applicator and method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
KR100263817B1 (ko) * 1993-11-30 2000-08-16 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
AU2003230836A1 (en) * 2002-04-08 2003-10-27 The Ohio State University Research Foundation Compounds and methods for inducing apoptosis in proliferating cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5954996A (en) 1994-07-13 1999-09-21 Centrix, Inc. Dental etch and package therefor
US20030203338A1 (en) 2002-04-24 2003-10-30 Levine Jonathan B. Tooth whitener applicator and method

Also Published As

Publication number Publication date
EP1696907B1 (en) 2013-04-17
WO2005044130A1 (en) 2005-05-19
DK1696907T3 (da) 2013-06-24
CN1889949B (zh) 2010-06-16
EP1696907A1 (en) 2006-09-06
EP1696907A4 (en) 2007-09-05
JP2007527408A (ja) 2007-09-27
ES2420405T3 (es) 2013-08-23
CA2566846C (en) 2012-08-28
CN1889949A (zh) 2007-01-03
JP4745971B2 (ja) 2011-08-10
KR20060108651A (ko) 2006-10-18
CA2566846A1 (en) 2005-05-19
WO2005044130A9 (en) 2005-09-15
SI1696907T1 (sl) 2013-12-31

Similar Documents

Publication Publication Date Title
US8039502B2 (en) Anti-infective agents against intracellular pathogens
US8546441B2 (en) PDK-1/AKT signaling inhibitors
KR101217427B1 (ko) Ｐｄｋ-1/ａｋｔ 신호전달 억제제
RU2249593C2 (ru) Пиразолбензодиазепины в качестве ингибиторов cdk2, промежуточные соединения для их получения и фармацевтическая композиция, их содержащая
Jin et al. Synthesis and anti-tumor activity of EF24 analogues as IKKβ inhibitors
JP2005528384A (ja) 増殖性細胞においてアポトーシスを誘導するための化合物および方法
KR20030015242A (ko) ＴＮＦ-α시그널링의 조절물질
RU2378250C2 (ru) Нестероидные модуляторы андрогенного рецептора, способ получения, их фармацевтическая композиция и применение
CN101514179A (zh) 吲哚酮亚乙基肼羰基化合物、其制备方法及其在医药上的应用
JP2020524659A (ja) 化合物
US6034099A (en) Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US11427574B2 (en) Compounds for treating Rac-GTPase mediated disorder
EP3634403B1 (en) Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
US9156790B2 (en) Anticancer P21-activated kinase inhibitors
US20210323927A1 (en) Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1
EP3901142A1 (en) Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1
JP2000109479A (ja) ジ置換マレイミド化合物及びその医薬用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20151207

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20161209

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20171212

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20241005

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION